Nivolumab plus Ipilimumab in Advanced MelanomaJedd D. Wolchok, Mario Sznol, Harriet M. Kluger et al.|New England Journal of Medicine|2013Cited by 4.2k
OncoKB: A Precision Oncology Knowledge BaseDebyani Chakravarty, Nikolaus Schultz, Jianjiong Gao et al.|JCO Precision Oncology|2017Cited by 2.7k
Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaMichael A. Postow, Jedd D. Wolchok, Christopher A. Barker et al.|New England Journal of Medicine|2012Cited by 2.1k
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z. Horvat, Paul B. Chapman, Nelly G. Adel et al.|Journal of Clinical Oncology|2015Cited by 1.1k
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodiesAlain P. Algazi, Ryan J. Sullivan, Katy K. Tsai et al.|Cancer|2016Cited by 375